{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:19:38Z","timestamp":1780471178376,"version":"3.54.1"},"reference-count":124,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Interleukin-17 (IL-17) is a cytokine family consisting of six members and five specific receptors. IL-17A was the first member to be identified in 1993. Since then, several studies have elucidated that IL-17 has predominantly pro-inflammatory activity and that its production is involved in both the defense against pathogens and the genesis of autoimmune processes. Materials and Methods: In this review, we provide an overview of the role of interleukin-17 in the pathogenesis of juvenile idiopathic arthritis (JIA) and its relationship with IL-23, the so-called IL-23\u2013IL-17 axis, by reporting updated findings from the scientific literature. Results: Strong evidence supports the role of interleukin-17A in the pathogenesis of JIA after the deregulated production of this interleukin by both T helper 17 (Th17) cells and cells of innate immunity. The blocking of IL-17A was found to improve the course of JIA, leading to the approval of the use of the human anti-IL17A monoclonal antibody secukinumab in the treatment of the JIA subtypes juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA). Conclusions: IL-17A plays a central role in the pathogenesis of JIA. Blocking its production with specific biologic drugs enables the effective treatment of this disabling childhood rheumatic disease.<\/jats:p>","DOI":"10.3390\/medicina58111552","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T09:01:42Z","timestamp":1667120502000},"page":"1552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The Role of Interleukin-17 in Juvenile Idiopathic Arthritis: From Pathogenesis to Treatment"],"prefix":"10.3390","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-9128","authenticated-orcid":false,"given":"Marino","family":"Paroli","sequence":"first","affiliation":[{"name":"Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Faculty of Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Spadea","sequence":"additional","affiliation":[{"name":"Post Graduate School of Public Health, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Caccavale","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Faculty of Medicine, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Spadea","sequence":"additional","affiliation":[{"name":"Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4395-4774","authenticated-orcid":false,"given":"Maria","family":"Paroli","sequence":"additional","affiliation":[{"name":"Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-9562","authenticated-orcid":false,"given":"Nicola","family":"Nante","sequence":"additional","affiliation":[{"name":"Post Graduate School of Public Health, University of Siena, 53100 Siena, Italy"},{"name":"Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-021-00332-8","article-title":"Juvenile idiopathic arthritis","volume":"8","author":"Martini","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-018-1571-6","article-title":"Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: Results from the Nordic cohort study","volume":"20","author":"Rypdal","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12969-017-0151-7","article-title":"Radiographic damage in hands and wrists of patients with juvenile idiopathic arthritis after 29 years of disease duration","volume":"15","author":"Selvaag","year":"2017","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"ref_4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13075-019-1950-7","article-title":"Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era","volume":"21","author":"Giancane","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: A novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"publisher","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: Structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J."},{"key":"ref_9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0968-0004(03)00067-7","article-title":"The STIR-domain superfamily in signal transduction, development and immunity","volume":"28","author":"Novatchkova","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"ref_10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20171849","article-title":"IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1(+) stem cells","volume":"216","author":"Chen","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.4049\/jimmunol.1102576","article-title":"Life before seventeen: Cloning of the IL-17 receptor","volume":"187","author":"Gaffen","year":"2011","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J. Immunol."},{"key":"ref_15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/cr.2007.35","article-title":"A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses","volume":"17","author":"Chang","year":"2007","journal-title":"Cell Res."},{"key":"ref_16","doi-asserted-by":"publisher","first-page":"7791","DOI":"10.4049\/jimmunol.179.11.7791","article-title":"An IL-17F\/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment","volume":"179","author":"Liang","year":"2007","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4049\/jimmunol.177.1.36","article-title":"Cutting edge: Interleukin 17 signals through a heteromeric receptor complex","volume":"177","author":"Toy","year":"2006","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.4049\/jimmunol.0903614","article-title":"IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis","volume":"184","author":"Hu","year":"2010","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/intimm\/dxab075","article-title":"Interleukin-17 family members in health and disease","volume":"33","author":"Chung","year":"2021","journal-title":"Int. Immunol."},{"key":"ref_20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"publisher","first-page":"12881","DOI":"10.1074\/jbc.M110.199547","article-title":"IL-17-induced NF-kappaB activation via CIKS\/Act1: Physiologic significance and signaling mechanisms","volume":"286","author":"Sonder","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"publisher","first-page":"5906","DOI":"10.4049\/jimmunol.1103233","article-title":"CIKS\/Act1-mediated signaling by IL-17 cytokines in context: Implications for how a CIKS gene variant may predispose to psoriasis","volume":"188","author":"Sonder","year":"2012","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mib.2017.10.016","article-title":"Inborn errors of immunity underlying fungal diseases in otherwise healthy individuals","volume":"40","author":"Li","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_25","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","article-title":"IL-17 Signaling: The Yin and the Yang","volume":"38","author":"Amatya","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"key":"ref_27","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1074\/jbc.M308809200","article-title":"Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members","volume":"279","author":"Ruddy","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.immuni.2015.06.024","article-title":"Growth Factor FGF2 Cooperates with Interleukin-17 to Repair Intestinal Epithelial Damage","volume":"43","author":"Song","year":"2015","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"publisher","first-page":"eaam8834","DOI":"10.1126\/sciimmunol.aam8834","article-title":"Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin","volume":"2","author":"Verma","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.semcdb.2018.01.008","article-title":"Organ-specific mechanisms linking innate and adaptive antifungal immunity","volume":"89","author":"Drummond","year":"2019","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/mi.2017.97","article-title":"Mucocutaneous IL-17 immunity in mice and humans: Host defense vs. excessive inflammation","volume":"11","author":"Li","year":"2018","journal-title":"Mucosal Immunol."},{"key":"ref_32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2011.09.010","article-title":"Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E","volume":"35","author":"Chang","year":"2011","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ni.2156","article-title":"IL-17C regulates the innate immune function of epithelial cells in an autocrine manner","volume":"12","author":"Sambandam","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"publisher","first-page":"108663","DOI":"10.1016\/j.celrep.2020.108663","article-title":"Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells","volume":"34","author":"Riether","year":"2021","journal-title":"Cell Rep."},{"key":"ref_37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_38","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nri2433","article-title":"Cytokine-mediated regulation of antimicrobial proteins","volume":"8","author":"Kolls","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"ref_40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1086\/422329","article-title":"Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice","volume":"190","author":"Huang","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.4049\/jimmunol.2000394","article-title":"An IL-17F.S65L Knock-In Mouse Reveals Similarities and Differences in IL-17F Function in Oral Candidiasis: A New Tool to Understand IL-17F","volume":"205","author":"Zhou","year":"2020","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"494","DOI":"10.4049\/jimmunol.162.1.494","article-title":"IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha","volume":"162","author":"Albanesi","year":"1999","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4049\/jimmunol.162.1.577","article-title":"Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors","volume":"162","author":"Antonysamy","year":"1999","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.4049\/jimmunol.165.11.6107","article-title":"Microbial lipopeptides induce the production of IL-17 in Th cells","volume":"165","author":"Horton","year":"2000","journal-title":"J. Immunol."},{"key":"ref_46","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cell.2012.09.016","article-title":"A validated regulatory network for Th17 cell specification","volume":"151","author":"Ciofani","year":"2012","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12026-007-8014-9","article-title":"Th17 cells: A new fate for differentiating helper T cells","volume":"41","author":"Chen","year":"2008","journal-title":"Immunol. Res."},{"key":"ref_50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/eji.201747102","article-title":"PKCepsilon promotes human Th17 differentiation: Implications in the pathophysiology of psoriasis","volume":"48","author":"Martini","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_51","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_52","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1074-7613(00)80645-7","article-title":"RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells","volume":"9","author":"He","year":"1998","journal-title":"Immunity"},{"key":"ref_56","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: From mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_57","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation","volume":"198","author":"Murphy","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_58","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nrrheum.2015.128","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_59","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/eji.202048627","article-title":"Tc17 biology and function: Novel concepts","volume":"50","author":"Picard","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"ref_60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.imlet.2016.05.001","article-title":"IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory disease","volume":"178","author":"Srenathan","year":"2016","journal-title":"Immunol. Lett."},{"key":"ref_61","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/ni.3726","article-title":"IL-17(+) gammadelta T cells as kick-starters of inflammation","volume":"18","author":"Papotto","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_62","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood-2013-11-427781","article-title":"Human innate lymphoid cells","volume":"124","author":"Hazenberg","year":"2014","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: The sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_64","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.4049\/jimmunol.1501541","article-title":"mTOR Mediates IL-23 Induction of Neutrophil IL-17 and IL-22 Production","volume":"196","author":"Chen","year":"2016","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3389\/fimmu.2018.00795","article-title":"A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It","volume":"9","author":"Tamassia","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.4049\/jimmunol.1302235","article-title":"Aspergillus and Fusarium corneal infections are regulated by Th17 cells and IL-17-producing neutrophils","volume":"192","author":"Taylor","year":"2014","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1128\/IAI.05493-11","article-title":"Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection","volume":"79","author":"Werner","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_68","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_70","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3899\/jrheum.141271","article-title":"A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate","volume":"42","author":"Pavelka","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/annrheumdis-2012-202646","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-016-0031-5","article-title":"Secukinumab: A New Treatment Option for Psoriatic Arthritis","volume":"3","author":"Mease","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"ref_73","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief Report: Interleukin-17 Blockade with Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses","volume":"70","author":"Menegatti","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"ref_75","doi-asserted-by":"publisher","first-page":"e20192048","DOI":"10.1084\/jem.20192048","article-title":"Interleukin-17 in rheumatoid arthritis: Trials and tribulations","volume":"217","author":"Taams","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_76","first-page":"40","article-title":"Risk adjusted mortality after hip replacement surgery: A retrospective study","volume":"53","author":"Messina","year":"2017","journal-title":"Ann. Dell\u2019istituto Super. Sanita"},{"key":"ref_77","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5539\/gjhs.v6n3p74","article-title":"Which factors influence functional patients improvements during rehabilitation?","volume":"6","author":"Messina","year":"2014","journal-title":"Glob. J. Health Sci."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Abd Almonaem, E.R., Shaheen, A.M., Abdelrahman, A.M.N., Hassan, W.A., Daay El Khair, N.M., and Abdel Haie, O.M. (2022). Association between Interleukin-17F 7488A\/G and 7383A\/G polymorphisms and susceptibility to juvenile idiopathic arthritis. Pediatr. Res.","DOI":"10.1038\/s41390-022-02288-1"},{"key":"ref_79","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_80","first-page":"343","article-title":"Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR)","volume":"35","author":"Behrens","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_81","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: Significance of early clinical and laboratory features","volume":"54","author":"Schneider","year":"2006","journal-title":"Arthritis Rheumatol."},{"key":"ref_82","first-page":"491","article-title":"Systemic onset juvenile idiopathic arthritis: A retrospective study of 80 consecutive patients followed for 10 years","volume":"27","author":"Lomater","year":"2000","journal-title":"J. Rheumatol."},{"key":"ref_83","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3899\/jrheum.150997","article-title":"The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010\u20132013","volume":"43","author":"Janow","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_84","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/rheumatology\/41.12.1444","article-title":"Long-term follow-up of 246 adults with juvenile idiopathic arthritis: Predictive factors for mood and pain","volume":"41","author":"Packham","year":"2002","journal-title":"Rheumatology"},{"key":"ref_85","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: Some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_86","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_87","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(17)30065-X","article-title":"Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: A multicentre, prospective, randomised, open-label trial","volume":"389","author":"Ravelli","year":"2017","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheumatol."},{"key":"ref_90","first-page":"289","article-title":"Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: Possible implications of immunotherapy","volume":"34","author":"Perisano","year":"2020","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_91","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: A cross-sectional study","volume":"66","author":"Hoppenreijs","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2018.01802","article-title":"T Cell Receptor-Independent, CD31\/IL-17A-Driven Inflammatory Axis Shapes Synovitis in Juvenile Idiopathic Arthritis","volume":"9","author":"Ferguson","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_93","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1136\/annrheumdis-2012-201388","article-title":"It is time to rethink juvenile idiopathic arthritis classification and nomenclature","volume":"71","author":"Martini","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_94","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/art.23291","article-title":"Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers","volume":"58","author":"Nistala","year":"2008","journal-title":"Arthritis Rheumatol."},{"key":"ref_95","doi-asserted-by":"publisher","first-page":"6435","DOI":"10.4049\/jimmunol.172.10.6435","article-title":"CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis","volume":"172","author":"Wedderburn","year":"2004","journal-title":"J. Immunol."},{"key":"ref_96","first-page":"515","article-title":"Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases","volume":"35","author":"Agarwal","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_97","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3899\/jrheum.081179","article-title":"Th1 and Th17 Predominance in the Enthesitis-related Arthritis Form of Juvenile Idiopathic Arthritis","volume":"36","author":"Mahendra","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_98","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3899\/jrheum.090066","article-title":"Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis","volume":"36","author":"Olivito","year":"2009","journal-title":"J. Rheumatol."},{"key":"ref_99","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/art.30332","article-title":"Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis","volume":"63","author":"Cosmi","year":"2011","journal-title":"Arthritis Rheumatol."},{"key":"ref_100","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.30331","article-title":"Interleukin-17 and Th17 cells: From adult to juvenile arthritis\u2014Now it is serious!","volume":"63","author":"Miossec","year":"2011","journal-title":"Arthritis Rheumatol."},{"key":"ref_101","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jmii.2014.07.002","article-title":"Persistent improper upregulation of Th17 and TReg cells in patients with juvenile idiopathic arthritis","volume":"49","author":"Wu","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_102","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/art.40731","article-title":"Innate Lymphoid Cells and T Cells Contribute to the Interleukin-17A Signature Detected in the Synovial Fluid of Patients with Juvenile Idiopathic Arthritis","volume":"71","author":"Rosser","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/rheumatology\/kes162","article-title":"Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis","volume":"51","author":"Omoyinmi","year":"2012","journal-title":"Rheumatology"},{"key":"ref_104","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/art.40099","article-title":"Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by gamma\/delta T Cells in Systemic Juvenile Idiopathic Arthritis","volume":"69","author":"Kessel","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_105","doi-asserted-by":"publisher","first-page":"e132508","DOI":"10.1172\/jci.insight.132508","article-title":"Th17 reprogramming of T cells in systemic juvenile idiopathic arthritis","volume":"5","author":"Henderson","year":"2020","journal-title":"JCI Insight"},{"key":"ref_106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4161\/mabs.1.3.8593","article-title":"Ustekinumab","volume":"1","author":"Cingoz","year":"2009","journal-title":"MAbs"},{"key":"ref_107","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/2040622318781760","article-title":"Ustekinumab in psoriatic arthritis and related phenotypes","volume":"9","author":"Roberts","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_108","doi-asserted-by":"publisher","first-page":"143","DOI":"10.12788\/j.sder.2018.040","article-title":"Ustekinumab for the treatment of psoriasis: An evidence update","volume":"37","author":"Yiu","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_109","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.gastrohep.2017.08.006","article-title":"Ustekinumab to treat Crohn\u2019s disease","volume":"40","author":"Gisbert","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_110","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/RHU.0000000000000408","article-title":"Ustekinumab as a Therapeutic Option for Children with Refractory Enthesitis-Related Arthritis","volume":"22","author":"Mannion","year":"2016","journal-title":"J. Clin. Rheumatol."},{"key":"ref_111","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: First global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"ref_112","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_113","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"ref_114","doi-asserted-by":"publisher","first-page":"884727","DOI":"10.3389\/fped.2022.884727","article-title":"New Insights on Juvenile Psoriatic Arthritis","volume":"10","author":"Brunello","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_115","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/acr.20508","article-title":"Enthesitis in an inception cohort of enthesitis-related arthritis","volume":"63","author":"Weiss","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_116","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/acr.24529","article-title":"Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis","volume":"74","author":"Weiss","year":"2022","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_117","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","article-title":"2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_118","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3899\/jrheum.160197","article-title":"Predicting Which Children with Juvenile Idiopathic Arthritis Will Have a Severe Disease Course: Results from the ReACCh-Out Cohort","volume":"44","author":"Guzman","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_119","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: Recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis","volume":"67","author":"Tse","year":"2015","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_121","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","article-title":"New Medications Are Needed for Children With Juvenile Idiopathic Arthritis","volume":"72","author":"Brunner","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"ref_122","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3899\/jrheum.120642","article-title":"Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"39","author":"Weiss","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_123","doi-asserted-by":"publisher","first-page":"620","DOI":"10.55563\/clinexprheumatol\/1u8y08","article-title":"Secukinumab in the treatment for patients with juvenile enthesitis related arthritis non-responsive to anti-TNF treatment according the Juvenile Spondyloarthritis Disease Activity Index","volume":"40","author":"Baer","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Brunner, H.I., Foeldvari, I., Alexeeva, E., Ayaz, N.A., Calvo Penades, I., Kasapcopur, O., Chasnyk, V.G., Hufnagel, M., Zuber, Z., and Schulert, G. (2022). Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: A randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann. Rheum. Dis.","DOI":"10.1136\/ard-2022-222849"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/11\/1552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:22Z","timestamp":1760144722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/11\/1552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":124,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["medicina58111552"],"URL":"https:\/\/doi.org\/10.3390\/medicina58111552","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}